<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34488546</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Expert review of vaccines</Title><ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation></Journal><ArticleTitle>Impact of the Delta variant on vaccine efficacy and response strategies.</ArticleTitle><Pagination><StartPage>1201</StartPage><EndPage>1209</EndPage><MedlinePgn>1201-1209</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14760584.2021.1976153</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The Delta variant of SARS-CoV-2 has caused a new wave of the COVID-19 epidemic in many countries. It is the most infectious variant of SARS-CoV-2 to date, and its high infectivity means that a higher proportion of the population needs to be vaccinated to reduce the disease burden, which poses a substantial public health challenge.</AbstractText><AbstractText Label="AREAS COVERED">The evolution of the Delta variant is reviewed, including an overview of the Delta Plus variant with a K417N mutation in the RBD, which may confer an improved immune evasion ability. Decreases in serum neutralizing antibody titers after vaccination against Delta were greater than those against Alpha but less than those against Beta. The protective efficacy of existing vaccines against the Delta variant have declined and is related to the number of doses and the time since vaccination.</AbstractText><AbstractText Label="EXPERT OPINION">The currently used vaccines are effective against hospitalization/severe disease due to the Delta variant. Accelerating the popularization of vaccination, improving the coverage rate, and the implementation of intervention measures, such as wearing masks, are effective means to control the spread of the Delta variant and other variants. However, vaccination alone against SARS-CoV-2 without intervention measures may lead to continuous spread and the emergence of new variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qiushuang</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Vaccines</MedlineTA><NlmUniqueID>101155475</NlmUniqueID><ISSNLinking>1476-0584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">neutralization</Keyword><Keyword MajorTopicYN="N">variant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>7</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34488546</ArticleId><ArticleId IdType="pmc">PMC8442750</ArticleId><ArticleId IdType="doi">10.1080/14760584.2021.1976153</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO 2021. SARS-COV-2 weekly epidemiological update.</Citation></Reference><Reference><Citation>The paper 2021. WHO: the world is at the early stage of the third round of epidemic. [accessed 2021Aug14] https://www.thepaper.cn/newsDetail_forward_13594892</Citation></Reference><Reference><Citation>ECDC . 2021. SARS-COV-2 Delta variant now dominant in much of the European region and efforts must be reinforced to prevent transmission, warn WHO/Europe and ECDC. July23.</Citation></Reference><Reference><Citation>Duong D.Alpha, Beta, Delta, Gamma: What&#x2019;s important to know about SARS-CoV-2 variants of concern? CMAJ. 2021;193(27):E1059&#x2013;E1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342008</ArticleId><ArticleId IdType="pubmed">34253551</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance. 2021;26(24). doi:10.2807/1560-7917.ES.2021.26.24.2100509.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.24.2100509</ArticleId><ArticleId IdType="pmc">PMC8212592</ArticleId><ArticleId IdType="pubmed">34142653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Deng A, Zhang Y, et al. Transmission dynamics of an outbreak of the SARS-COV-2 Delta variant B.1.617.2 &#x2014; Guangdong province, China, May&#x2013;June 2021. China CDC Weekly. 2021;3(27):584&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8392962</ArticleId><ArticleId IdType="pubmed">34594941</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184(16):4220&#x2013;4236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8218332</ArticleId><ArticleId IdType="pubmed">34242578</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P, Kemp S, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant emergence, replication and sensitivity to neutralising antibodies. bioRxiv. 2021. doi:10.1101/2021.05.08.443253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.08.443253</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis C, Logan N, Tyson G, et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. medRxiv. 2021. doi:10.1101/2021.06.23.21259327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.23.21259327</ArticleId><ArticleId IdType="pmc">PMC8639073</ArticleId><ArticleId IdType="pubmed">34855916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Hofmann-Winkler H, Kr&#xfc;ger N, et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. bioRxiv. 2021. doi:10.1101/2021.05.04.442663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.04.442663</ArticleId><ArticleId IdType="pmc">PMC8238662</ArticleId><ArticleId IdType="pubmed">34270919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada T, Zhou H, Dcosta BM, et al. The ppike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal Antibodies. bioRxiv. 2021. doi:10.1101/2021.05.14.444076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.14.444076</ArticleId></ArticleIdList></Reference><Reference><Citation>Health SoIMo  (2021) The novel coronavirus. [cited 2021 Aug
14]
https://govextra.gov.il/ministry-of-health/corona/corona-virus-en</Citation></Reference><Reference><Citation>Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv. 2021. doi:10.1101/2021.06.30.21259439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.30.21259439</ArticleId><ArticleId IdType="pmc">PMC8584828</ArticleId><ArticleId IdType="pubmed">34774196</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreen S, Chung H, He S, et al. Effectiveness of SARS-COV-2 vaccines against variants of concern in Ontario, Canada. medRxiv. 2021. doi:10.1101/2021.06.28.21259420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.28.21259420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2021;581(7807):215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascarella S, Ciccozzi M, Zella D, et al. SARS-CoV-2 B.1.617 Indian variants: are electrostatic potential changes responsible for a higher transmission rate? J Med Virol. 2021. doi:10.1002/jmv.27210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27210</ArticleId><ArticleId IdType="pmc">PMC8426736</ArticleId><ArticleId IdType="pubmed">34260088</ArticleId></ArticleIdList></Reference><Reference><Citation>Motozono C, Toyoda M, Zahradnik J, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe. 2021;29(7):1124&#x2013;1136.e1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205251</ArticleId><ArticleId IdType="pubmed">34171266</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021;184(13):3426&#x2013;3437.e3428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057738</ArticleId><ArticleId IdType="pubmed">33991487</ArticleId></ArticleIdList></Reference><Reference><Citation>Motozono C, Toyoda M, Zahradnik J, et al. An emerging SARS-CoV-2 variant evading cellular immunity and increasing viral infectivity. bioRxiv. 2021. doi:10.1101/2021.04.02.438288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.02.438288</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M, Bassi J, De Marco A, et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. 2021;373(6555):648&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9835956</ArticleId><ArticleId IdType="pubmed">34210893</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Greaney AJ, Dingens AS, et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2(4):100255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020059</ArticleId><ArticleId IdType="pubmed">33842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchesnokova V, Kulakesara H, Larson L, et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv. 2021. doi:10.1101/2021.02.22.432189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.22.432189</ArticleId><ArticleId IdType="pmc">PMC8525575</ArticleId><ArticleId IdType="pubmed">34379531</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giacomo S, Mercatelli D, Rakhimov A, et al. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS&#x2010;CoV&#x2010;2) Spike mutation T478K. J Med Virol. 2021;93(9):5638&#x2013;5643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242375</ArticleId><ArticleId IdType="pubmed">33951211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Chen J, Gao K, et al. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other SARS-COV-2-devastated countries. Genomics. 2021;113(4):2158&#x2013;2170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8123493</ArticleId><ArticleId IdType="pubmed">34004284</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch F, Weisblum Y, Barnes CO, et al. Development of potency, breadth and resilience to viral escape mutations of SARS-CoV-2 neutralizing antibodies. bioRxiv. 2021. doi:10.1101/2021.03.07.434227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.07.434227</ArticleId><ArticleId IdType="pmc">PMC8323339</ArticleId><ArticleId IdType="pubmed">34331873</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117(21):11727&#x2013;11734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260975</ArticleId><ArticleId IdType="pubmed">32376634</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier LE, Lubinski B, Tang T, et al. Spike protein cleavage-activation mediated by the SARS-CoV-2 P681R mutation: a case-study from its first appearance in variant of interest (VOI) A.23.1 identified in Uganda. bioRxiv. 2021. doi:10.1101/2021.06.30.450632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.30.450632</ArticleId><ArticleId IdType="pmc">PMC9430374</ArticleId><ArticleId IdType="pubmed">35766497</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito A, Irie T, Suzuki R, et al. SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity. bioRxiv. 2021. doi:10.1101/2021.06.17.448820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.17.448820</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratev F.The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a Free energy of perturbation study. bioRxiv. 2020. doi: 10.1101/2020.12.23.424283</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.23.424283</ArticleId><ArticleId IdType="pubmed">34806876</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune evasion. Cell. 2021;184(9):2362&#x2013;2371.e2369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901273</ArticleId><ArticleId IdType="pubmed">33735608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African SARS-COV-2 donor plasma. Nat Med. 2021;27(4):622&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348&#x2013;2361.e2346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901269</ArticleId><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>Calloway E. (news) . Delta coronavirus variant: scientists brace for impact. Nat News.2021June22;595(7865):17&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">34158664</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus&#x2013;infected pneumonia. New Engl J Med. 2020;382(13):1199&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Deng A, Li K, et al. Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant. medRxiv. 2021. doi:10.1101/2021.07.07.21260122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.07.21260122</ArticleId><ArticleId IdType="pmc">PMC8786931</ArticleId><ArticleId IdType="pubmed">35075154</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas J, Fidler S. Some vaccinated people are dying of SARS-CoV-2. Here&#x2019;s why scientists aren&#x2019;t surprised. Wall Street J. [cited 2021&#xa0;Aug&#xa0;14]. Available from: https://www.msn.com/en-us/health/medical/some-vaccinated-people-are-dying-of-covid-19-heres-why-scientists-arent-surprised/ar-AALHnqO</Citation></Reference><Reference><Citation>England PH . 2021. SARS-CoV-2 variants of concern and variants under investigation in England (Technical briefing 14) 3June</Citation></Reference><Reference><Citation>Fisman DN, Tuite AR. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada. medRxiv. 2021. doi:10.1101/2021.07.05.21260050</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.05.21260050</ArticleId><ArticleId IdType="pmc">PMC8562985</ArticleId><ArticleId IdType="pubmed">34610919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall EC, Wu M, Harvey R, et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet. 2021;398(10296):207&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238446</ArticleId><ArticleId IdType="pubmed">34197809</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkal GN, Yadav PD, Sahay RR, et al. Neutralization of Delta variant with sera of Covishield vaccinees and SARS-COV-2 recovered vaccinated individuals. bioRxiv. 2021. doi:10.1101/2021.07.01.450676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.01.450676</ArticleId><ArticleId IdType="pmc">PMC8385819</ArticleId><ArticleId IdType="pubmed">34343316</ArticleId></ArticleIdList></Reference><Reference><Citation>Jongeneelen M, Kaszas K, Veldman D, et al. Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern. bioRxiv. 2021. doi:10.1101/2021.07.01.450707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.01.450707</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH, Stephenson KE, Sadoff J, et al. Durable humoral and cellular immune responses following Ad26.COV2.S vaccination for SARS-COV-2. medRxiv. 2021. doi:10.1101/2021.07.05.21259918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.05.21259918</ArticleId><ArticleId IdType="pmc">PMC8314733</ArticleId><ArticleId IdType="pubmed">34260834</ArticleId></ArticleIdList></Reference><Reference><Citation>Haveri A, Ekstr&#xf6;m N, Solastie A, et al. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection. medRxiv. 2021. doi:10.1101/2021.07.13.21260426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.13.21260426</ArticleId><ArticleId IdType="pmc">PMC8646652</ArticleId><ArticleId IdType="pubmed">34580856</ArticleId></ArticleIdList></Reference><Reference><Citation>Carre&#xf1;o JM, Alshammary H, Singh G, et al. Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37. medRxiv. 2021. doi:10.1101/2021.07.21.21260961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.21.21260961</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">34111888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331&#x2013;2333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175044</ArticleId><ArticleId IdType="pubmed">34090624</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi A, Koch M, Wu K, et al. Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants. bioRxiv. 2021. doi:10.1101/2021.06.28.449914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.28.449914</ArticleId><ArticleId IdType="pmc">PMC8577347</ArticleId><ArticleId IdType="pubmed">34549975</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav PD, Sapkal GN, Ella R, et al. Neutralization against B.1.351 and B.1.617.2 with sera of SARS-COV-2 recovered cases and vaccinees of BBV152. bioRxiv. 2021. doi:10.1101/2021.06.05.447177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.05.447177</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected SARS-COV-2 patients. medRxiv. 2021. doi:10.1101/2021.07.10.21260232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.10.21260232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Wei X-Y, Xiang J, et al. Reduced neutralization of SARS-CoV-2 B.1.617 variant by inactivated and RBD-subunit vaccine. bioRxiv. 2021. doi:10.1101/2021.07.09.451732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.09.451732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Zheng A, Li D, et al. Neutralization of recombinant RBD-subunit vaccine ZF2001-elicited antisera to SARS-CoV-2 variants including Delta. bioRxiv. 2021. doi:10.1101/2021.07.15.452504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.15.452504</ArticleId><ArticleId IdType="pmc">PMC8378832</ArticleId><ArticleId IdType="pubmed">34458880</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia PY, Xiang Ong SW, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. medRxiv. 2021. doi:10.1101/2021.07.28.21261295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.28.21261295</ArticleId><ArticleId IdType="pmc">PMC8608661</ArticleId><ArticleId IdType="pubmed">34826623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New Engl J Med. 2020; ;NEJMoa2109072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal JL, Andrews N, Gower C, et al. Effectiveness of SARS-COV-2 vaccines against the B.1.617.2 variant. medRxiv. 2021. doi:10.1101/2021.05.22.21257658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.22.21257658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8201647</ArticleId><ArticleId IdType="pubmed">34139198</ArticleId></ArticleIdList></Reference><Reference><Citation>TOI STAFF . Israel confirms vaccine less effective against Delta variant, eyes third dose. The Times of Israel. [cited 2021 Aug
14]https://www.timesofisrael.com/israel-confirms-vaccine-less-effective-against-delta-variant-eyes-third-dose</Citation></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and SARS-COV-2 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhong NS. (2021). Guangzhou summarized five points in its prevention and control experience in dealing with the Delta variant for the first time. [cited 2021 Aug
14]http://news.ycwb.com/2021-06/26/content_40102369.ht</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>